Search
Palazestrant
go.drugbank.com/drugs/DB18971InvestigationalPalazestrant is under investigation in clinical trial NCT06016738 (OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
Lexaptepid pegol
go.drugbank.com/drugs/DB12578InvestigationalLexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
Cilazaprilat
go.drugbank.com/drugs/DB15565ExperimentalCategories: Agents Acting on the Renin-Angiotensin SystemLerociclib
go.drugbank.com/drugs/DB16218InvestigationalLerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast
EB05
go.drugbank.com/drugs/DB16477InvestigationalEB05, in combination with standard of care (SOC), is being investigated in clinical trial NCT04401475 to evaluate its safety and efficacy in adult hospitalized patients with COVID-19 and ARDS.
Uproleselan
go.drugbank.com/drugs/DB14829Investigationalin AML). … Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy
Categories: E-Selectin, antagonists & inhibitorsEpiVacCorona
go.drugbank.com/drugs/DB16439InvestigationalIt is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613]. … EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608].
Categories: Complex MixturesATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Masitinib
go.drugbank.com/drugs/DB11526InvestigationalVet approvedMasitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. … In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Synonyms: 4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE